跳转至内容
Merck
CN

R130

RJR-2403 hemigalactarate

≥98% (HPLC), powder

别名:

N-Methyl-4-(3-pyridinyl]-3-buten-1-amine hemigalactarate

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C20H28N4 · C6H10O8
化学文摘社编号:
分子量:
534.60
UNSPSC Code:
12352200
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: 1 mg/mL, H2O: 20 mg/mL

storage temp.

2-8°C

SMILES string

CNCC\C=C\c1cccnc1

Biochem/physiol Actions

Neuronal nicotinic acetylcholine receptor agonist that displays CNS activity.

Disclaimer

Photosensitive


法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Pharmacological characterization of RJR-2403: A nicotinic agonist with potential therapeutic benefit in the treatment of Alzheimer's disease.
Bencherif, M.
Cns Drug Reviews, 3, 325-325 (1997)
P M Lippiello et al.
The Journal of pharmacology and experimental therapeutics, 279(3), 1422-1429 (1996-12-01)
We have evaluated the physiological and behavioral effects of the CNS-selective nicotinic agonist (E)-N-methyl-4-(3-pyridinyl) -3-butene-1-amine (RJR-2403) using a number of different methods, including 1) reversal of pharmacologically induced amnesia in a step-through passive avoidance paradigm, 2) radial arm maze performance
M Bencherif et al.
The Journal of pharmacology and experimental therapeutics, 279(3), 1413-1421 (1996-12-01)
Increasing evidence for an involvement of nicotinic cholinergic systems in neurodegenerative disorders has stimulated the search for compounds with selectivity for CNS nicotinic ACh receptors (nAChRs). To this end, we have evaluated a number of nicotinic agonists for their ability